Skip to main content
NBP
NASDAQ Life Sciences

NovaBridge Biosciences Highlights Strong Clinical Data & Extends Cash Runway to Q4 2028

Analysis by Wiseek AI
Sentiment info
Positive
Importance info
9
Price
$3.24
Mkt Cap
$374.696M
52W Low
$0.595
52W High
$6.79
Market data snapshot near publication time

Summary

NovaBridge Biosciences released an updated investor presentation showcasing robust Phase 1b oncology data for Givastomig, promising interim Phase 2 ophthalmology data for VIS-101, and a solid financial position with cash runway extended to Q4 2028.


Key Events

  • Robust Oncology Data

    Givastomig Phase 1b data shows 75% Objective Response Rate (ORR) and 16.9-month median Progression-Free Survival (mPFS) in 1L Gastroesophageal Adenocarcinoma (GEA), reinforcing its best-in-class potential. A randomized Phase 2 study is initiating in Q1 2026.

  • Promising Ophthalmology Pipeline

    VIS-101 interim Phase 2 data indicates rapid and sustained vision improvement, with topline results expected in Q1 2026 and readiness to initiate Phase 3 by the end of 2026.

  • Extended Financial Runway

    The company reports $228.3 million in cash, cash equivalents, and short-term investments as of September 30, 2025, providing operational runway until Q4 2028.


Analysis

This updated investor presentation provides a comprehensive overview of NovaBridge Biosciences' pipeline progress and financial health. The strong efficacy and durability data for Givastomig in Phase 1b, coupled with its best-in-class potential, significantly de-risks the lead oncology program. Positive interim Phase 2 results for VIS-101 further validate the company's ophthalmology platform. Crucially, the disclosed cash runway extending to Q4 2028 provides substantial operational stability, reducing near-term financing concerns and allowing the company to advance its clinical programs without immediate dilution pressure. Investors should monitor upcoming data readouts for VIS-101 in Q1 2026 and the initiation of Givastomig's randomized Phase 2 study.

At the time of this filing, NBP was trading at $3.24 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $374.7M. The 52-week trading range was $0.60 to $6.79. This filing was assessed with positive market sentiment and an importance score of 9 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

NBP - Latest Insights

NBP
Apr 28, 2026, 4:05 PM EDT
Filing Type: 4
Importance Score:
8
Price at Filing: $2.56
Real-time Price: $1.51 info
Change: -$1.05 (-41%) info
Market Cap: $171.919M info
NBP
Apr 22, 2026, 7:05 AM EDT
Filing Type: 6-K
Importance Score:
7
Price at Filing: $2.62
Real-time Price: $1.51 info
Change: -$1.11 (-42%) info
Market Cap: $171.919M info
NBP
Apr 07, 2026, 4:50 PM EDT
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $2.48
Real-time Price: $1.51 info
Change: -$0.970 (-39%) info
Market Cap: $171.919M info
NBP
Apr 07, 2026, 4:48 PM EDT
Filing Type: 20-F
Importance Score:
9
Price at Filing: $2.52
Real-time Price: $1.51 info
Change: -$1.01 (-40%) info
Market Cap: $171.919M info
NBP
Mar 16, 2026, 8:30 AM EDT
Filing Type: 6-K
Importance Score:
8
Price at Filing: $3.18
Real-time Price: $1.51 info
Change: -$1.67 (-52%) info
Market Cap: $171.919M info
NBP
Mar 09, 2026, 7:05 AM EDT
Filing Type: 6-K
Importance Score:
9
Price at Filing: $3.81
Real-time Price: $1.51 info
Change: -$2.30 (-60%) info
Market Cap: $171.919M info
NBP
Mar 09, 2026, 7:00 AM EDT
Source: GlobeNewswire
Importance Score:
9
Price at Filing: $3.81
Real-time Price: $1.51 info
Change: -$2.30 (-60%) info
Market Cap: $171.919M info
NBP
Mar 03, 2026, 9:13 AM EST
Filing Type: 6-K
Importance Score:
7
Price at Filing: $3.36
Real-time Price: $1.51 info
Change: -$1.85 (-55%) info
Market Cap: $171.919M info
NBP
Feb 25, 2026, 7:30 AM EST
Filing Type: 6-K
Importance Score:
9
Price at Filing: $3.24
Real-time Price: $1.51 info
Change: -$1.73 (-53%) info
Market Cap: $171.919M info
NBP
Feb 19, 2026, 7:05 AM EST
Filing Type: 6-K
Importance Score:
7
Price at Filing: $3.29
Real-time Price: $1.51 info
Change: -$1.78 (-54%) info
Market Cap: $171.919M info